These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 27282405)
1. Deletion of Gab2 in mice protects against hepatic steatosis and steatohepatitis: a novel therapeutic target for fatty liver disease. Chen S; Kang Y; Sun Y; Zhong Y; Li Y; Deng L; Tao J; Li Y; Tian Y; Zhao Y; Cheng J; Liu W; Feng GS; Lu Z J Mol Cell Biol; 2016 Dec; 8(6):492-504. PubMed ID: 27282405 [TBL] [Abstract][Full Text] [Related]
2. The role of hepassocin in the development of non-alcoholic fatty liver disease. Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031 [TBL] [Abstract][Full Text] [Related]
4. Puerarin ameliorates hepatic steatosis by activating the PPARα and AMPK signaling pathways in hepatocytes. Kang OH; Kim SB; Mun SH; Seo YS; Hwang HC; Lee YM; Lee HS; Kang DG; Kwon DY Int J Mol Med; 2015 Mar; 35(3):803-9. PubMed ID: 25605057 [TBL] [Abstract][Full Text] [Related]
5. Hepatitis B Virus X Protein Induces Hepatic Steatosis by Enhancing the Expression of Liver Fatty Acid Binding Protein. Wu YL; Peng XE; Zhu YB; Yan XL; Chen WN; Lin X J Virol; 2016 Feb; 90(4):1729-40. PubMed ID: 26637457 [TBL] [Abstract][Full Text] [Related]
6. SNX10 mediates alcohol-induced liver injury and steatosis by regulating the activation of chaperone-mediated autophagy. You Y; Li WZ; Zhang S; Hu B; Li YX; Li HD; Tang HH; Li QW; Guan YY; Liu LX; Bao WL; Shen X J Hepatol; 2018 Jul; 69(1):129-141. PubMed ID: 29452206 [TBL] [Abstract][Full Text] [Related]
10. Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease. Lin Y; Ding D; Huang Q; Liu Q; Lu H; Lu Y; Chi Y; Sun X; Ye G; Zhu H; Wei J; Dong S Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):869-882. PubMed ID: 28483554 [TBL] [Abstract][Full Text] [Related]
11. Oleic acid protects saturated fatty acid mediated lipotoxicity in hepatocytes and rat of non-alcoholic steatohepatitis. Chen X; Li L; Liu X; Luo R; Liao G; Li L; Liu J; Cheng J; Lu Y; Chen Y Life Sci; 2018 Jun; 203():291-304. PubMed ID: 29709653 [TBL] [Abstract][Full Text] [Related]
12. Gab2 mediates hepatocellular carcinogenesis by integrating multiple signaling pathways. Cheng J; Zhong Y; Chen S; Sun Y; Huang L; Kang Y; Chen B; Chen G; Wang F; Tian Y; Liu W; Feng GS; Lu Z FASEB J; 2017 Dec; 31(12):5530-5542. PubMed ID: 28842424 [TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic fatty liver disease induced by noncanonical Wnt and its rescue by Wnt3a. Wang S; Song K; Srivastava R; Dong C; Go GW; Li N; Iwakiri Y; Mani A FASEB J; 2015 Aug; 29(8):3436-45. PubMed ID: 25917329 [TBL] [Abstract][Full Text] [Related]
14. Liver-specific suppressor of cytokine signaling-3 deletion in mice enhances hepatic insulin sensitivity and lipogenesis resulting in fatty liver and obesity. Sachithanandan N; Fam BC; Fynch S; Dzamko N; Watt MJ; Wormald S; Honeyman J; Galic S; Proietto J; Andrikopoulos S; Hevener AL; Kay TW; Steinberg GR Hepatology; 2010 Nov; 52(5):1632-42. PubMed ID: 20799351 [TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271 [TBL] [Abstract][Full Text] [Related]
16. Elovl6 promotes nonalcoholic steatohepatitis. Matsuzaka T; Atsumi A; Matsumori R; Nie T; Shinozaki H; Suzuki-Kemuriyama N; Kuba M; Nakagawa Y; Ishii K; Shimada M; Kobayashi K; Yatoh S; Takahashi A; Takekoshi K; Sone H; Yahagi N; Suzuki H; Murata S; Nakamuta M; Yamada N; Shimano H Hepatology; 2012 Dec; 56(6):2199-208. PubMed ID: 22753171 [TBL] [Abstract][Full Text] [Related]
17. Swertiamarin ameliorates oleic acid induced lipid accumulation and oxidative stress by attenuating gluconeogenesis and lipogenesis in hepatic steatosis. Patel TP; Rawal K; Soni S; Gupta S Biomed Pharmacother; 2016 Oct; 83():785-791. PubMed ID: 27490779 [TBL] [Abstract][Full Text] [Related]
18. Deletion of steroid receptor coactivator-3 gene ameliorates hepatic steatosis. Ma X; Xu L; Wang S; Cui B; Li X; Xu J; Ning G J Hepatol; 2011 Aug; 55(2):445-52. PubMed ID: 21184786 [TBL] [Abstract][Full Text] [Related]